Capacity Expansion
Phase III Manufacturing Suite Now Operational

Our new 30,000 sq ft Phase III GMP synthesis suite has passed FDA pre-approval inspection, expanding our commercial-scale peptide API capacity by 60%.
All NewsPriority Sales Hotline
Tap to chat with us
Capacity Expansion

Our new 30,000 sq ft Phase III GMP synthesis suite has passed FDA pre-approval inspection, expanding our commercial-scale peptide API capacity by 60%.
All NewsWe use cookies
We use essential cookies to make our site work, and optional analytics & preference cookies to improve your experience. See our Cookie Policy.